Strange Bedfellows: Generics Firms Join Big Pharma In Opposing US Price Negotiation Legislation

 
• By Cathy Kelly

Concerns that Medicare drug price negotiation provisions in the Build Back Better legislation would upend the US generic and biosimilar industries might resonate with legislators more than complaints from branded drug companies.

The Innovator And Off-Patent Sectors Are Often Not On The Same Side • Source: Alamy

More from Policy & Regulation

More from Generics Bulletin